KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovoCure (NVCR) EPS (Weighted Average and Diluted) (2018 - 2025)

NovoCure's EPS (Weighted Average and Diluted) history spans 8 years, with the latest figure at -$0.22 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 63.93% year-over-year to -$0.22; the TTM value through Dec 2025 reached -$1.22, up 21.79%, while the annual FY2025 figure was -$1.22, 21.79% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.22 at NovoCure, up from -$0.33 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.04 in Q1 2021 and bottomed at -$0.61 in Q4 2024.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.31 (2024), against an average of -$0.31.
  • The largest annual shift saw EPS (Weighted Average and Diluted) crashed 1150.0% in 2023 before it soared 63.93% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.25 in 2021, then crashed by 44.0% to -$0.36 in 2022, then fell by 22.22% to -$0.44 in 2023, then plummeted by 38.64% to -$0.61 in 2024, then soared by 63.93% to -$0.22 in 2025.
  • Per Business Quant, the three most recent readings for NVCR's EPS (Weighted Average and Diluted) are -$0.22 (Q4 2025), -$0.33 (Q3 2025), and -$0.36 (Q2 2025).